Repare Therapeutics Inc 's ROA from the third quarter of 2025 to the third quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Repare Therapeutics Inc 's ROA in the third quarter of 2025?
Repare Therapeutics Inc recorded a cumulative net loss of $-72 million during 12 months ending in the third quarter of 2025, resulting in a negative return on assets (ROA) of -50.32%.

However, within the Healthcare sector 573 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2025 quarter, so far to 4246, from total ROA ranking in the second quarter of 2025 at 4327.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter	(Sep 30 2024) III. Quarter
Y / Y Total Assets Change	-39.52 %	-44.2 %	-45.76 %	-51.37 %	-27.59 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-72	-110	-128	-85	-84
Return On Assets (TTM)	-50.32 %	-67.06 %	-67.43 %	-38.54 %	-31.56 %
RPTX's Total Ranking	# 4246	# 4327	# 4635	# 4029	# 3847
Total Assets (TTM) in million	124	130	143	176	206
Seq. Total Assets Change	-4.65 %	-8.53 %	-19.13 %	-14.26 %	-12.02 %
Seq. Net Income Change	-	-	-	-	-

RPTX's 5 Years Annual ROA >> Back to RPTX Management Effectiveness >> Compare RPTX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 249
Sector	# 574
Overall	# 4022

Return On Assets Statistics
High	Average	Low
-0.87 %	-29.09 %	-67.11 %
(Jun 30 2023)		(Mar 31 2025)

Financial Statements
Repare Therapeutics Inc 's Assets	$ 124 million	RPTX's Balance sheet
Repare Therapeutics Inc 's Income	$ 3 million	Quarterly RPTX's Income Statement
RPTX's Income by Division		See RPTX's Income by Division

Annual Return On Assets	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020
Y / Y Total Assets Change	-29.77 %	-30.27 %	0.33 %	1.56 %	-
Total Assets in million	176	251	360	359	354
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-85	-94	-29	-107	-53
Annual Return On Assets	-48.01 %	-37.34 %	-8.06 %	-29.78 %	-15.11 %

RPTX's 5 Years Annual ROA >> Back to RPTX Management Effectiveness >> Compare RPTX ROA to its Competitors

More Return On Assets Ratios
RPTX's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
RPTX's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for RPTX's Competitors
Subscribers only: Roa for Repare Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for RPTX's Customers

You may also want to know
RPTX's Roi	RPTX's Inventory Turnover Ratio	RPTX's Growth Rates	RPTX's Dividend Comparisons
	RPTX's Profitability Ratios	RPTX's Asset Turnover Ratio	RPTX's Dividend Growth
RPTX's Roe	RPTX's Valuation Ratios	RPTX's Financial Strength Ratios	RPTX's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2025, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:38:34+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.